Clinical Characteristics of Patients With Anti-Collapsin Response Mediator Protein 2 Antibodies i… (NCT07036042) | Clinical Trial Compass
CompletedNot Applicable
Clinical Characteristics of Patients With Anti-Collapsin Response Mediator Protein 2 Antibodies in Encephalitis or Encephalomyelitis
China300 participantsStarted 2022-06-01
Plain-language summary
Autoimmune encephalitis (AE) is an important autoimmune neurological disease, and its clinical manifestations, treatment and prognosis are closely related to the type of pathogenic antibodies. However, due to the limited antibody spectrum and the unclear pathogenic mechanism, the disease is difficult to diagnose and treat, and the morbidity and mortality rates are high. In a previous study, we found that anti-CRMP2 antibodies were AE-specific autoantibodies, adding a new member to the AE antibody spectrum and thus defining a new class of AEs, anti-CRMP2 encephalitis. However, due to the limited number of cases, its clinical characteristics such as incidence, concomitant diseases, imaging manifestations, treatment effects and prognosis are not yet clear. This study plans to conduct large-scale anti-CRMP2 antibody screening in critically ill patients with suspected neurological autoimmune diseases in our hospital, and compare the clinical differences between anti-CRMP2 encephalitis and other known AEs and non-autoimmune encephalitis.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The inclusion criteria for patients are illustrated: 1) patients admitted to the Department of Neurology,or the Neurocritical Unit (NCU) of Nanfang Hospital, Southern Medical University, between January 2017 and November 2019; 2) patients with suspected immune-mediated encephalopathy (altered consciousness persisting for more than 24 hours) or myelopathy. This included cases of encephalopathy suspected to be autoimmune, infectious or metabolic as well as encephalopathy with unclear etiology; 3) patients with remaining serum and/or cerebrospinal fluid (CSF) samples available for immunoreaction analysis using tissue-based assay (TBA) and cell-based assay (CBA). All samples were the first obtained from patients after hospitalization, prior to initiating treatment at our hospital. Some patients, however, may have received treatment at other hospitals before being transferred here.
The exclusion criteria were: 1) loss to follow-up; 2) incomplete data; 3) encephalopathy resulting from toxic, traumatic, anoxic/hypoxic, genetic, or endocrine causes.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Antibodies CRMP2 detected in blood or cerebrospinal fluid
Timeframe: 2024.12
Trial details
NCT IDNCT07036042
SponsorNanfang Hospital, Southern Medical University